A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Congress : ESMO

Authors : H. Bonnefoi, C. Levy, G. MacGrogan, T. Grellety, B. Asselain, M. Pulido, S. Everhard, J.Lemonnier, A. Gonçalves

Experts group or program : French Breast Cancer Intergroup (UCBG)

Up to 36% of triple-negative breast cancer (TNBC) are androgen receptor (AR)-positive (≥ 10% by immuno-histochemistry, IHC). When these tumours metastasise, several clinical trials assessing antagonists of the AR or androgen synthesis suppressor showed promising clinical benefit rates (CBR). Darolutamide is a novel, effective and well tolerated AR antagonist tested in prostate cancer clinical trials. Thus we aim to assess clinical activity and safety of darolutamide in AR-positive TNBC.

En savoir plus